The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [(18) F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.

A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer / S. Valtorta, G. Nicolini, F. Tripodi, C. Meregalli, G. Cavaletti, F. Avezza, L. Crippa, G. Bertoli, P. Fusi, F. Orsini, R. Pagliarin, R. M. Moresco, P. Coccetti. - In: INVESTIGATIONAL NEW DRUGS. - ISSN 1573-0646. - 32:6(2014), pp. 1123-1133.

A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer

F. Orsini;R. Pagliarin;
2014

Abstract

The anticancer activity of a novel pure 1,4-Diaryl-2-azetidinone (1), endowed with a higher solubility than the well known Combretastatin A4, is tested in mice. We previously reported that Compound (1) showed specific antiproliferative activity against duodenal and colon cancer cells, inducing activation of AMP-activated protein kinase and apoptosis. Here we estimate that the maximum tolerated dose in a mouse model is 40 mg/kg; the drug is well tolerated both in single dose and in repeated administration schedules. The drug displays a significant antitumor activity and a tumor growth delay when administered at the MTD both in single and fractionated i.v. administration in a mouse xenograft model of colorectal cancer. Arrest of tumor growth and relapse after drug suspension are parallel to modification in glucose demand as shown by PET studies with [(18) F] FDG. These data strongly support Compound (1) as a promising molecule for in vivo treatment of colorectal cancer.
Azetidinones; Colorectal cancer; Combretastatin A4 (CA-4); PET; Xenograft
Settore CHIM/06 - Chimica Organica
Settore BIO/10 - Biochimica
Article (author)
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs10637-014-0148-8.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.17 MB
Formato Adobe PDF
2.17 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/256039
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact